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Recombinant baculoviruses (rBV) expressing Ebola virus VP40 (rBV-VP40) or GP (rBV-GP) proteins were generated. Infection of Sf9 insect
cells by rBV-VP40 led to assembly and budding of filamentous particles from the cell surface as shown by electron microscopy. Ebola virus-like
particles (VLPs) were produced by coinfection of Sf9 cells with rBV-VP40 and rBV-GP, and incorporation of Ebola GP into VLPs was
demonstrated by SDS-PAGE and Western blot analysis. Recombinant baculovirus infection of insect cells yielded high levels of VLPs, which
were shown to stimulate cytokine secretion from human dendritic cells similar to VLPs produced in mammalian cells. The immunogenicity of
Ebola VLPs produced in insect cells was evaluated by immunization of mice. Analysis of antibody responses showed that most of the GP-specific
antibodies were of the IgG2a subtype, while no significant level of IgG1 subtype antibodies specific for GP was induced, indicating the induction
of a Th1-biased immune response. Furthermore, sera from Ebola VLP immunized mice were able to block infection by Ebola GP pseudotyped
HIV virus in a single round infection assay, indicating that a neutralizing antibody against the Ebola GP protein was induced. These results show
that production of Ebola VLPs in insect cells using recombinant baculoviruses represents a promising approach for vaccine development against
Ebola virus infection.
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Viruses of four distinct families, arenaviruses, filoviruses,
bunyaviruses, and flaviviruses have been found to cause viral
hemorrhagic fevers (VHFs), a group of diseases with common
symptoms including fever, fatigue, and muscle ache in mild
cases and hemorrhage, shock, coma, seizures, and death in
severe cases (Borio et al., 2002; Geisbert and Jahrling, 2004).
Ebola virus is a member of the filoviridae family and causes
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doi:10.1016/j.virol.2006.03.021mortality rate up to 90%, for which no effective treatment or
vaccine is available at present (Feldmann et al., 2003). The
current outbreak of Marburg virus, another member of the
filoviridae family, which has caused infection of almost 400
people with more than 300 fatalities in Angola (WHO, 2005),
further emphasizes the urgent need to development an effective
vaccine strategy against the Ebola virus as well as the closely
related Marburg virus. The immune response that can provide
an effective protection against Ebola or Marburg virus infection
and pathogenesis has not been clearly defined and accumulated
evidence suggests that both antibody and cellular immune
responses will be required (Hart, 2003; Nabel, 2003). However,
a number of vaccine strategies including inactivated virus, viral
protein subunits, DNA, VLPs, as well as recombinant viral
vector-based vaccines are under development and have
produced promising results (Enserink, 2003; Feldmann et al.,
2003; Geisbert and Jahrling, 2003; Hart, 2003). Immunization
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Marburg proteins has been shown to confer protection against
lethal challenge in animal models (Hevey et al., 1998; Pushko et
al., 2000; Sullivan et al., 2000, 2003). Although the success of
these viral vector-based vaccine strategies provides hope for the
containment of emergency outbreaks, the preexisting immune
response against these viral vectors may reduce their efficacy in
human applications. Moreover, the induction of immune
responses against viral vector antigens may limit or preclude
the possibility of boosting immunity for obtaining long-lasting
protection or the successful vaccination against a different strain
should it arise in future. These limitations of viral vector-based
vaccines underscore the need for the development of alternative
vaccines that can be administered repetitively.
Filoviruses are a family of enveloped, nonsegmented
negative-stranded RNA viruses encoding 7 proteins, of which
the glycoprotein GP is the only protein that forms the spikes on
the surfaces of mature virions and mediates virus entry into the
cell (Elliott et al., 1993; Sanchez et al., 1993). The Ebola GP is a
type I transmembrane protein which is cleaved into two
subunits (GP1 and GP2) by a cellular protease during transport
to the cell surface (Sanchez et al., 1998; Volchkov et al., 1998).
Infection of cells by Ebola virus leads to assembly and budding
of filamentous virus particles (Bavari et al., 2002). The Ebola
matrix protein VP40 is the most abundant protein in the virions
and has been shown to provide the driving force for the
formation of filamentous virus particles (Jasenosky et al., 2001;
Noda et al., 2002). Like the matrix proteins or Gag proteins of
other enveloped RNA viruses, Ebola VP40 possesses late
domains containing the PTAP and PPXY motifs, which interact
with the WW domains of cellular proteins such as Nedd4 and
TSg101 and play critical roles in the assembly of virus particles
(Freed, 2002). It has been shown that expression of Ebola VP40
alone resulted in efficient assembly and budding of Ebola virus-
like particles (VLPs) from mammalian cells (Jasenosky et al.,
2001; Noda et al., 2002). Furthermore, coexpression of Ebola
VP40 and GP proteins results in release of Ebola VLPs in
mammalian cell lines (Bavari et al., 2002; Jasenosky et al.,
2001; Noda et al., 2002). However, expression of GP alone also
results in release of pleiomorphic vesicles containing GP spikes
on their surfaces (Noda et al., 2002). VLPs for both Ebola and
Marburg viruses produced in mammalian cells have been shown
to confer effective protections against lethal challenges in
animal models (Swenson et al., 2005; Warfield et al., 2003,
2004), indicating that the VLPs represent a promising vaccine
strategy for the control and prevention of filovirus infection and
associated hemorrhagic fevers.
VLPs of several viruses have been successfully produced
from insect cells using recombinant baculoviruses, and these
VLPs have been shown to induce both antibody and cellular
immune responses when used to immunize animals (Bertolotti-
Ciarlet et al., 2003; Li et al., 1997; Park et al., 2003; Yao et al.,
2002). In this study, we investigated the assembly and release of
Ebola VLPs from insect cells using recombinant baculoviruses
expressing VP40 and GP proteins and characterized the
antibody responses induced by these VLP preparations in
mice. Our results show that Ebola VLPs produced in insect cellsexhibit the ability to stimulate cytokine secretion from dendritic
cells, and immunization with these Ebola VLPs can induce
neutralizing antibodies against the Ebola GP protein. Produc-
tion of VLPs in insect cells gives high yields and can be easily
adapted for large-scale production, thus representing an
attractive approach for the development of an effective vaccine
against Ebola virus infection.
Results
Expression of VP40 in insect cells leads to budding and release
of EBOV VLPs
We have shown in previous studies that expression of HIVor
SIV Gag proteins in insect cells by infection with recombinant
baculoviruses leads to assembly and release of VLPs that are
morphologically similar to those observed in mammalian cells
(Yamshchikov et al., 1995; Yao et al., 2001, 2003). To
investigate whether expression of VP40 in insect cells can
also lead to assembly of Ebola VLPs, Sf9 insect cells were
infected with rBV-VP40 at an MOI of 2 and at 24 h post-
infection, the cells were fixed, sectioned, and examined under a
transmission electron microscope. As shown in Fig. 1A,
infection of Sf9 cells with rBV-VP40 led to formation and
budding of filamentous Ebola VLPs from the cell surface as
detected by electron microscopy. These filamentous VLPs are
about 70 nm in diameter and 800 to 1500 nm in length, which
are similar in size and morphology to the virus particles
observed in Ebola virus infected cells (Bavari et al., 2002),
indicating that the VP40 protein alone is sufficient for assembly
of VLPs when expressed in insect cells. Furthermore, as shown
in Fig. 1B, filamentous virus-like particles were observed in the
VLP preparations from SF9 cells infected with rBV-VP40 and
rBV-GP, similar to those observed budding from the cells (Fig.
1A). Similar filamentous particles were also observed in the
VLP preparations from the supernatant of Sf9 cells infected
with rBV-VP40 alone (not shown). On the other hand,
pleiomorphic vesicles that are 70 to 150 nm in diameter were
observed in the medium from Sf9 cells infected with rBV-GP
alone (Fig. 1C).
Production and characterization of Ebola VLPs produced in
insect cells
For large-scale production of VLPs, Sf9 cells (2 × 106/ml)
were infected with rBV-VP40 alone or rBV-VP40 and rBV-GP
together at an MOI of 2 and 5 respectively, and VLPs were
purified in a discontinuous sucrose gradient (10–50%). A
visible band between the 30% and 50% sucrose layers was
collected, concentrated by ultracentrifugation and then resus-
pended in PBS giving a final protein concentration of 1 μg/μl.
We compared the protein profiles of Ebola VLP preparations
from Sf9 cells infected with rBV-VP40 and rBV-GP and the
preparations from Sf9 cells infected with rBV-VP40 or rBV-GP
alone. VLP preparations from Sf9 cells infected with rBV-Gag
(expressing the simian immunodeficiency virus Gag protein)
were used as a control. As shown in Fig. 2A, analysis of the
Fig. 1. (A) Budding of Ebola VLPs from insect cells. Sf9 cells were infected with rBV-VP40. At 24 h post-infection, the cells were fixed with 2% glutaraldehyde and
then with 2% osmium tetroxide. Thin-section samples were prepared and stained with 1% uranyl acetate followed by examination under a transmission electron
microscope. (B) Negative staining of Ebola VLPs. (C) Negative staining of pleiomorphic GP vesicles. Sf9 cells were infected with rBV-VP40 along with rBV-GP (B)
or rBV-GP alone (C). At 48 h post-infection, medium was collected, and VLPs or GP vesicles in medium were purified by centrifugation through a 10–50% sucrose
gradient and the visible bands containing VLPs or GP vesicles were collected, concentrated by centrifugation and resuspended in PBS at a protein concentration of
1 μg/μl. The samples were stained with 1% uranyl acetate followed by examination under a transmission electron microscope. Arrows indicate elongated VLPs in
panels A and B.
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mixture of monoclonal antibodies against VP40 and GP
proteins showed that both VP40 and GP are present in the
VLP preparations produced by coinfection of Sf9 cells with
rBV-VP40 and rBV-GP. As expected, only the VP40 protein or
GP protein was detected in the preparations from cells infected
with rBV-VP40 or rBV-GP alone respectively. The Ebola GP
protein expressed in mammalian cells is synthesized as a
precursor and then cleaved into two subunits, GP1 and GP2,
which are linked by a disulfide bond (Sanchez et al., 1998;
Volchkov et al., 1998). The antibody against GP is specific for
the GP1 subunit. To investigate whether the GP proteins in theFig. 2. (A) Western blot analysis of Ebola VLP preparations. Sf9 cells were infected w
rBV-VP40 and rBV-GP (lane 4). The VLP preparations were resuspended in PBS a
reducing protein sample buffer, heated at 95 °C for 5 min, and then subjected to
antibodies against Ebola VP40 and GP proteins. (B) Mobility of the GP protein in SD
Ebola VP40-GP VLPs (5 μg) were mixed with reducing (with β-mercaptoethanol, lan
heated at 95 °C for 5 min, and then subjected to SDS-PAGE followed by Western bl
VLPs mixed with nonreducing protein sample buffer were used as controls (lane 1). (C
was mixed with reducing protein sample buffer, heated at 95 °C for 5 min, and then su
weight marker; lane 1, VP40-GP VLPs; lane 2, GP vesicle preparations.VLP preparations produced in insect cells are cleaved, we
compared the mobility of GP protein in VLP preparations in the
presence or absence of the reducing reagent β-mercaptoethanol.
As shown in Fig. 2B, the GP protein exhibited a faster mobility
by SDS-PAGE after treatment with β-mercaptoethanol, indi-
cating that it was efficiently cleaved in insect cells. Protein
profiles for VP40-GP and GP VLPs were also examined by
SDS-PAGE and Coomassie blue staining. As shown in Fig. 2C,
VP40 proteins are readily detected in VP40-GP VLPs.
However, GP proteins were not detected in either VLP
preparation, probably due to the lower relative levels of GP in
VLPs and/or inefficient staining of glycoproteins by Coomassieith rBV-SIV-Gag (control VLP, lane 1); rBV-VP40 (lane 2); rBV-GP (lane 3); or
t the concentration of 1 μg/μl and 5 μg of VLP preparations were mixed with
SDS-PAGE followed by Western blot analysis using a mixture of monoclonal
S-PAGE in the presence or absence of the reducing reagent β-mercaptoethanol.
e 3) or nonreducing (without β-mercaptoethanol, lane 2) protein sample buffers,
ot analysis using a monoclonal antibody against the Ebola GP protein. SIV-Gag
) Coomassie blue staining of Ebola VLP preparations. 5 μg of VLP preparations
bjected to SDS-PAGE followed by Coomassie blue staining. Lane M, molecular
263L. Ye et al. / Virology 351 (2006) 260–270blue. A protein band about 60Kd in molecular weight was also
detected by Coomassie blue staining in both VP40-GP and GP
VLPs, which is probably baculovirus glycoprotein GP64 based
on its apparent molecular weight.
To demonstrate that the GP proteins are incorporated into the
VLPs, 5 μg of VLP preparations from the supernatant of Sf9
cells infected with rBV-VP40 and rBV-GP as well as rBV-VP40
or rBV-GP alone was loaded on top of a discontinuous sucrose
gradient (10–50%) followed by centrifugation at 30K RPM for
1 h in a Beckman SW41 rotor. Fractions were collected, and the
proteins in these fractions were concentrated and analyzed by
SDS-PAGE and Western blot. As shown in Fig. 3, the majority
of both VP40 and GP in the VLP preparation from rBV-VP40
and rBV-GP infected cells cosedimented in fractions 3 to 6.
Similarly, the majority of VP40 in the VLP preparation from
rBV-VP40 infected cells was also detected in fractions 3 to 6. On
the other hand, the majority of GP from the rBV-GP infection
was detected in fractions 5 to 7. These result showed that the
majority of the released GP proteins from cells expressing both
VP40 and GP proteins colocalized with the VP40 proteins in the
sucrose gradient and sedimented at a higher density compared
with the released GP proteins from cells infected with rBV-GP
alone, indicating that the GP proteins are incorporated into VLPs
formed by the VP40 proteins.
Stimulation of cytokine secretion from dendritic cells (DCs) by
Ebola VLPs
To determine whether Ebola VLPs produced in insect cells
are able to stimulate cytokine secretion by DCs, more DCs were
incubated with VP40-GP VLPs, VP40 only VLPs, GP vesicle
preparations, as well as LPS (positive control) or medium only
(negative control) for 24 h, and the amounts of cytokines
secreted into the medium were determined by ELISA. As shown
in Fig. 4, incubating DCs with Ebola VP40-GP VLPs induced
secretion of cytokines and chemokines such as IL-6, IL10, IL-
12, and TNF-alpha. The levels of IL-6 and TNF-alpha inducedFig. 3. Distribution of VP40 and GP proteins from different preparations in a sucr
supernatant of Sf9 cells infected with rBV-VP40 plus rBV-GP as well as rBV-VP40
ultracentrifugation. Six 2-ml fractions (lanes 1 to 6, from the top to the bottom) as w
gradient. Proteins in these fractions were concentrated by centrifugation and then an
antibodies against Ebola VP40 and GP proteins.by VP40-GP VLPs are similar to those induced by LPS, while
the level of IL-12 is higher, and the level of IL-10 is lower than
the levels induced by LPS, respectively. These results indicate
that the Ebola VLPs produced in insect cells exhibited the
biological activity of DC-stimulation. Furthermore, incubating
DCs with preparations from Sf9 cells infected with rBV-GP
alone (which consist of pleiomorphic GP vesicles as shown in
Fig. 1C) also induced secretion of similar levels of TNF-alpha
as well as significantly lower levels of IL-12 and IL-6 compared
with VP4-GP VLPs, but no IL-10. On the other hand,
incubating DCs with VLPs containing VP40 only did not
induce secretion of any cytokines at detectable levels. These
results demonstrate that the presence of GP in the VLPs is
critical for their DC-stimulating activity, and that the pleio-
morphic GP vesicles also exhibit DC-stimulating activity
although at a reduced level.
Induction of antibody responses by immunization with Ebola
VLPs
The immunogenicity of the VLPs produced in insect cells
was evaluated by immunization of mice in comparison with the
GP only preparations, which also exhibit DC-stimulating
activity but at a reduced level compared with VLPs. Mice
were immunized intramuscularly 3 times at 4-week intervals
with 50 μg of Ebola VP40-GP VLPs or with the pleiomorphic
GP vesicles. As shown in Fig. 2A, the GP vesicle preparation
contained similar or slightly higher levels of GP proteins than
the same amount of VLP preparation. Serum samples were
collected at 2 weeks after each immunization and the levels of
antibody responses specific for the Ebola virus GP were
determined by ELISA using purified Ebola GP1-histag fusion
proteins as coating antigens. As shown in Fig. 5, significant
levels of antibodies against Ebola virus GP1 proteins were
induced after two immunizations with VP40-GP VLPs, and the
levels of antibody response were significantly boosted by the
third immunization. In contrast, immunization with GP vesiclesose gradient. VLPs or GP vesicles preparations (5 μg each) purified from the
or rBV-GP alone were loaded on top of a 10–50% sucrose gradient followed by
ell as the pellet (lanes 7) were collected after centrifugation through the sucrose
alyzed by SDS-PAGE followed by Western blot using a mixture of monoclonal
Fig. 4. Ebola VLPs stimulate cytokine secretion by dendritic cells (DCs). Human myeloid DCs were prepared from human PBMC as described in Materials and
Methods. DCs were obtained from two healthy donors and incubated with different VLP preparations in duplicates for each DC preparation. DCs incubated with
culture medium only were used as negative controls and DCs incubated with LPS (10 ng/ml) were used as positive controls. Cell-free supernatants were harvested 24 h
after incubation and assayed for the levels (pg/ml) of TNF-alpha, IL-6, IL10 and IL-12 by ELISA in duplicates. Control, cell culture medium (mock control); LPS,
10 ng/ml (positive control); GP, GP vesicle preparations (10 μg/ml); VP40, VP40 only VLPs (10 μg/ml); Ebo VLP, Ebola VLPs produced in Sf9 insect cells (10 μg/
ml). The results shown represent typical results obtained from two different stimulation experiments and error bars represent standard deviations. Significance of
statistical differences in the levels of secreted cytokines stimulated by Ebola VLPs or GP vesicle preparations was determined by a t test.
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response after three immunizations, and the levels of antibody
response were significantly lower (more than 3-fold) compared
with the VP40-GP VLPs. Moreover, it is interesting to note that
most of the Ebola GP-specific antibodies induced by VP40-GP
VLPs or GP vesicle preparations were of the IgG2a subtype,
while the levels of IgG1 antibodies were not significantly higher
than those induced in the control group, indicating the induction
of a strong Th1-biased immune response.
To assess whether the antibodies induced by VP40-GP VLPs
or GP vesicle preparations can neutralize virus infection, we
employed a pseudotype virus-neutralization assay adapted from
an HIV neutralization assay system as described in our previous
studies (Bu et al., 2004; Ye et al., 2004). Env-deficient HIV
virus was pseudotyped with Ebola GP protein by cotransfection
of 293T cells with a DNA vector expressing Ebola GP and the
HIV cDNA, in which a frameshift deletion mutation was
introduced in the env gene. The ability of the Ebola GP to
mediate infection of JC53 cells, a cell line expressing β-gal
under the control of the HIV LTR (Derdeyn et al., 2000; Wei et
al., 2003), was determined by counting the number of β-gal-
expressing cells. Infection of JC53BL cells by GP-pseudotyped
virus was completely blocked by hyper-immune mouse sera
against Ebola virus at over 1:1000 dilution (data not shown),
indicating that the entry of the pseudotyped viruses into the cells
is mediated by the Ebola GP protein. As shown in Fig. 6, sera
from both VP40-GP VLP- and GP vesicle-immunized mice
exhibited a neutralizing activity of about 80% at 1:40 dilution
while sera from the control mice did not show significant levels
of neutralizing activity against the pseudotyped virus. However,
the neutralizing activity of sera from GP vesicle-immunized
mice dropped drastically to about 35% at 1:80 dilution and
further dropped to about 15% at 1:160 dilution which is notsignificant over the background levels. In contrast, the
neutralizing activity of sera from VP40-GP VLP-immunized
mice remained over 50% at 1:160 dilution, which is
significantly higher than the neutralizing activity of sera from
GP VLP-immunized mice at the same dilution. These results
correlate with the levels of GP-specific antibodies induced by
VP40-GP VLPs and GP vesicle preparations and show that
Ebola VLPs produced in insect cells using the recombinant
baculovirus expression system can induce neutralizing anti-
bodies that can prevent Ebola GP protein-mediated virus
infection.
Ebola VLPs produced in insect cells or mammalian cells
exhibit similar abilities to stimulate cytokine secretion from
DCs
It has been reported that Ebola VLPs produced in
mammalian cells stimulate cytokine secretion from human
DCs (Bosio et al., 2004). The results from the above studies
show that Ebola VLPs produced in insect cells also exhibit DC-
stimulating activities. It has been noted that protein glycosyl-
ation differs between insect and mammalian cells (Jarves and
Finn, 1995). We thus produced Ebola VLPs by transfection of
293T cells for direct comparison with Ebola VLPs produced in
insect cells. As shown in Fig. 7, similar levels of Ebola GP and
VP40 proteins were detected in Ebola VLPs produced in the Sf9
insect cells or mammalian 293T cells. Moreover, the GP protein
in Sf9 cell-produced VLPs exhibited a faster migration rate than
the GP protein in 293T cell-produced VLPs in SDS-PAGE
(comparing lane 2 and lane 3), probably due to differences in
glycosylation. We further compared DC-stimulating activities
between Ebola VLPs produced in Sf9 insect cells and
mammalian 293T cells. As shown in Fig. 8, similar levels of
Fig. 6. Neutralization of Ebola GP pseudotyped HIV by sera from immunized
mice. Serum samples obtained from mice (groups of 6) immunized with PBS,
GP vesicle preparations, or VP40-GP VLPs at two weeks after the third
immunization were heat-inactivated and mixed with 100 pfu of Ebola GP-
pseudotyped HIVat 1:40, 1:80, or 1:160 dilutions and incubated at 37 °C for 1 h
and then added to JC53 cells. At 48 h post-infection, the cells were stained for β-
galactosidase expression by addition of X-Gal, and the numbers of blue cells
were counted under a light microscope. The percentages of reduction in the
number of blue cells in comparison to the control wells were calculated as
described in Materials and Methods. Standard deviations for serum samples
from each mouse of the group were shown. Significance of statistical differences
in neutralizing activity at 1:160 dilution of serum samples from mice immunized
with VP40-GP VLPs or GP vesicle preparations was determined by a t test.
Fig. 5. Antibody responses against Ebola GP protein induced by immunization
with VLPs or GP vesicles. Mice (groups of 6) were immunized intramuscularly
with 50 μg of VLP preparations three times at 4-week intervals. Serum samples
were collected at 2 weeks after each immunization (open bars, after the first
immunization; gray bars, after the second immunization; and black bars, after
the third immunization) and assayed for Ebola GP specific antibodies by ELISA
using purified Ebola GP1 as coating antigen. A standard curve was generated
using purified mouse antibodies for each mouse antibody subtype and used for
calculation of the equivalent amount of GP-binding antibodies in serum
samples. Group 1, immunized with PBS; group 2, immunized with GP
preparations; group 3, immunized with VP40-GP VLPs. Error bars represent
standard deviations among individual mouse serum samples in each group.
Significance of statistical differences in the levels of antibody responses induced
by immunization with VP40-GP VLPs or GP vesicle preparations was
determined by t test.
Fig. 7. Western blot analysis of Ebola VLPs produced in Sf9 insect cells and
293T mammalian cells. Ebola VLPs produced in insect cells were carried out by
coinfection of Sf9 cells with rBV-VP40 and rBV-GP. Ebola VLPs produced in
mammalian cells were carried out by cotransfection of 293T cells with DNA
expression vectors pcDNA3-VP40 and pcDNA3-GP. The VLP preparations
were resuspended in PBS, and 5 μg of VLP preparations was mixed with
reducing protein sample buffer, heated at 95 °C for 5 min, and then subjected to
SDS-PAGE followed by Western blot analysis using a mixture of monoclonal
antibodies against Ebola VP40 and GP proteins. Lanes 1, SIV Gag VLPs
produced in Sf9 cells (control); 2, Ebola VLPs produced in Sf9 insect cells; 3,
Ebola VLPs produced in 293T mammalian cells.
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TNFa were detected in the medium of DCs stimulated with
Ebola VLPs produced in Sf9 cells or 293T cells. Moreover, the
levels of secreted IL6 and TNFa from DCs stimulated by VLPs
produced in Sf9 cells relative to stimulation by LPS were
similar to those observed in Fig. 4, despite the use of different
batches of VLPs and LPS in these experiments. On the other
hand, DCs stimulated with Ebola VLPs produced in mammalian
293T cells secreted higher levels of IL10, an anti-inflammatory
cytokine (Pestka et al., 2004). However, whether this difference
in IL10 stimulation is due to the differences in glycosylation or
other differences in VLPs produced in different cell typesremains to be determined. Furthermore, DCs stimulated with
Ebola VLPs produced in Sf9 or 239T cells also showed similar
upregulation of activation makers such as CD80 and CD83 as
detected by FACS analysis (data not shown). Taken together,
these results show that Ebola VLPs produced in Sf9 insect cells
or mammalian 293T cells contain similar profiles of Ebola GP
and VP40 proteins and exhibit similar DC-stimulating activities
Fig. 8. Ebola VLPs produced in Sf9 insect cells or 293T mammalian cells exhibit similar activities to stimulate cytokine secretion by dendritic cells (DCs). Dendritic
cells were prepared from human PBMC and incubated with VLPs produced in Sf9 insect cells or mammalian 293T cells as described in Materials and Methods. DCs
were obtained from two healthy donors and incubated with different VLP preparations in duplicates for each DC preparation. DCs incubated with culture medium only
were used as negative controls and DCs incubated with LPS (10 ng/ml) were used as positive controls. Cell-free supernatants were harvested 24 h after incubation and
assayed for the levels (pg/ml) of IL-6, IL-8, IL10, IL-12, and TNF-alpha by ELISA in duplicates. Control, cell culture medium (mock control); LPS, 10 ng/ml (positive
control); Ebo VLP, Ebola VLPs produced in Sf9 insect cells (10 μg/ml); Ebo VLPm, Ebola VLPs produced in mammalian 293T cells (10 μg/ml). The results shown
represent typical results obtained from at least two different stimulation experiments and error bars represent standard deviations.
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two cell types.
Discussion
In this study, we investigated the assembly of Ebola VLPs in
insect cells using recombinant baculoviruses. Our results show
that expression of VP40 alone or together with GP in insect cells
led to efficient assembly and release of VLPs, which exhibit a
filamentous structure resembling Ebola virions. On the other
hand, expression of Ebola GP alone in insect cells led to release
of pleiomorphic vesicles. Previous studies on Ebola VLP
assembly and budding in mammalian cells also indicated that
the expression of VP40 is essential and sufficient for driving the
formation of filamentous particles (Jasenosky et al., 2001; Noda
et al., 2002). We observed that by coexpression with VP40, GP
was found to cosediment with VP40 in a sucrose gradient, and
exhibited a different sedimentation pattern from GP vesicles,
indicating that the GP proteins were incorporated into the VLPs
formed by the VP40 proteins. Moreover, the GP proteins in
VLPs were found to be efficiently processed into the GP1 and
GP2 subunits that are linked by disulfide bonds. The yield for
purified VLPs produced in Sf9 insect cells was typically
between 5 to 10 mg/l of cell culture, which is similar to theyields we consistently obtained for HIV and SIV VLPs
(Yamshchikov et al., 1995; Yao et al., 2001). In contrast, we
found that production of HIV VLPs in mammalian cells using
recombinant vaccinia viruses gave a yield of about 1 mg/l of cell
culture (unpublished observations), and it has been reported that
the yield for HIV VLP production in a stable cell line is less than
1 mg/l of tissue culture medium (Montefiori et al., 2001).
One of the distinctive properties of Ebola VLPs is their
ability to stimulate DCs or macrophages to secret cytokines. It
has been reported that Ebola VLPs produced in mammalian
cells but not inactivated Ebola virions can stimulate production
and secretion of proinflammatory cytokines such as IL-6, IL-8,
and TNF-alpha by DCs (Bosio et al., 2004; Warfield et al.,
2003). This property of the Ebola VLPs has been suggested to
play an important role in eliciting protective immune responses,
since immunization with VLPs but not inactivated virions was
found to confer effective protection against lethal Ebola virus
challenge despite induction of similar levels of neutralizing
antibodies in immunized animals (Warfield et al., 2003). In this
study, we found that the VP40-GP VLPs produced in insect
cells were able to stimulate cytokine secretion by DCs, and the
levels of secreted cytokines from DCs stimulated with Ebola
VLPs produced in Sf9 insect cells were similar to those from
DCs stimulated with Ebola VLPs produced in mammalian 293T
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stimulate any detectable cytokine secretion, indicating that the
presence of GP is critical for the observed cytokine stimulation
activity. It is interesting to note that glycoproteins synthesized in
insect cells lack modification by complex carbohydrates, and
the side chains are of the high-mannose type (Mellquist-
Riemenschneider et al., 2003). Our results suggest that the
glycosylation difference between mammalian and insect cells
does not significantly affect the ability of Ebola VLPs to
stimulate cytokine secretion by DCs, indicating that the Ebola
VLPs produced in insect cells possess similar functional
activities to those produced in mammalian cells. It has been
reported that, unlike Ebola VLPs, the purified Ebola GP
proteins could not stimulate cytokine secretion by macrophages
(Wahl-Jensen et al., 2005). However, we observed that the GP
vesicle preparations devoid of VP40 were also able to stimulate
cytokine secretion by DCs, although at reduced levels. Taken
together, these observations suggest that the presentation of
Ebola GP proteins in a membrane bound or multivalent form
may be required for exhibiting DC-stimulating activity, and the
higher DC-stimulating activity observed for VP40-GP VLPs
may result from a relatively more ordered arrangement of GP
proteins on the membrane surface of VLPs.
Evaluation of immunogenicities in mice showed that both
VP40-GP VLPs and GP vesicle preparations induced antibody
responses against GP in immunized animals that are mainly of
the IgG2a subtype, indicating the induction of strong Th1-
biased immune responses. However, immunization with the
VP40-GP VLPs induced significantly higher levels of antibody
response than the GP vesicle preparation. It has been shown that
the glycoprotein of vesicular stomatitis virus presented in a
highly repetitive form in virus particles is more potent in
inducing B cell response and antibody production than the same
antigen presented in a poorly organized form (Bachmann et al.,
1993; Bachmann and Zinkernagel, 1996). Therefore, it is
possible that the GP proteins in Ebola VLPs are presented in a
more ordered arrangement and thus are more potent in eliciting
antibody responses as well as in stimulating cytokine secretion
by DCs. On the other hand, the higher levels of antibody
response induced by VP40-GP VLPs may be due to their
enhanced abilities to stimulate DCs, the professional antigen
presenting cells. The Ebola GP protein expressed in insect cells
has been shown to bind to monoclonal antibodies against
different epitopes (Mellquist-Riemenschneider et al., 2003). We
observed that both VP40-GP VLPs and the GP vesicle
preparations induced neutralizing antibodies that can block
virus infection mediated by the Ebola GP protein, indicating
that the neutralizing epitopes are preserved in the Ebola GP
proteins synthesized in insect cells. Sera from VP40-GP VLP
immunized mice neutralized about 80% infectivity of Ebola
GP-pseudotyped HIV pseudovirions at 1:40 dilutions and about
50% infectivity at 1:160 dilution. This is similar in range to the
neutralizing titers of sera from mice immunized with Ebola
VLPs produced in mammalian 293T cell, which were shown to
neutralize 50% infectivity of Ebola virus at about 1:100
dilutions as reported by Warfield et al. (2003). In agreement
with the levels of GP-specific antibody responses, sera frommice immunized with VP40-GP VLPs exhibited significantly
higher levels of neutralizing activities than sera from mice
immunized with the GP vesicle preparations.
VLPs for both Ebola and Marburg viruses produced in
mammalian cells have been shown to confer effective protection
in small animal models against lethal challenge (Swenson et al.,
2005; Warfield et al., 2003). Furthermore, a recent study
showed that immunization with Ebola VLPs produced in
mammalian cells induced both antibody and T cell responses
against GP and VP40 proteins, and both humoral and cellular
immune responses induced by Ebola VLPs are critical in
conferring protection against lethal challenge (Warfield et al.,
2005). The results reported in this study showed that Ebola
VLPs produced in insect cells exhibit DC-stimulating activities
and can induce neutralizing antibodies against the Ebola GP
protein similar to VLPs produced in mammalian cells, despite
known differences in glycosylation between mammalian cells
and insect cells. However, it remains to be determined whether
insect-cell-produced Ebola VLPs exhibit similar immunogeni-
cities as mammalian-cell-produced VLPs in eliciting both
humoral and cellular immune responses and conferring
protection against Ebola virus infection. VLPs can be
administered repeatedly to vaccinated individuals and the
nonreplicative nature of VLPs and their lack of viral genomic
RNA make them safe for broad and repeated application, and
they thus represent an attractive vaccine strategy against
filovirus infection. Production of Ebola VLPs in insect cells
using recombinant baculoviruses gives high yield and the
production process can be easily adapted for large-scale
manufacture, offering an attractive approach for the develop-
ment of an effective and economical vaccine strategy to prevent
Ebola virus infection.
Materials and methods
Cells and antibodies
Spodoptera frugiperda Sf9 cells were cultured in SF-900 II
serum-free medium with penicillin/streptomycin in suspension.
Monoclonal antibodies against Ebola VP40 and GP proteins
were kindly provided by Dr. Y. Kawaoka.
Generation of recombinant baculoviruses
Recombinant baculoviruses expressing Ebola VP40 or GP
proteins were generated following similar procedures as
described in our previous studies (Yamshchikov et al.,
1995). The cDNAs for Ebola GP and VP40 proteins (Ebola
Zaire strain, Mayinga isolate, kindly provided by Dr. P. Rollin,
Center for Disease Control and Prevention) were amplified by
PCR and cloned into the plasmid vector pBlueScript IIKS
under the T7 promoter and confirmed by sequencing. These
genes were then cloned into an AcMNPV transfer vector pC/
pS1 under the control of a hybrid capsid/polyhedrin promoter
(Pcap/polh), and these plasmids were used to generate
recombinant baculoviruses rBV-VP40 and rBV-GP expressing
Ebola VP40 or GP proteins, respectively. Sf9 cells were
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baculovirus transfer vector pC/pS1 containing Ebola VP40 or
GP genes respectively by using a BacGold Cotransfection Kit
(Invitrogen) following the manufacturer's instruction. Recom-
binant baculoviruses were plaque purified and expanded in
Sf9 cells to generate virus stocks, and the titers were
determined using a Fastplax Assay Kit (Invitrogen).
Protein expression and VLP production in insect cells
Sf9 cells in suspension cultures were infected with rBV-
VP40 or rBV-GP alone or coinfected with rBV-VP40 plus rBV-
GP at the MOIs (multiplicity of infection) of 2 for rBV-VP40
and 5 for rBV-GP respectively. Media were harvested 48 h post-
infection and clarified by centrifugation at 6000 rpm for 30 min.
Supernatants were ultracentrifuged at 28,000 rpm for 1 h, the
VLPs in the pellets were resuspended in PBS and further
purified on a discontinuous 10–50% (w/v) sucrose gradient. A
visible band between the 30% and 50% sucrose layers was
collected, concentrated by centrifugation and then resuspended
in PBS at a final protein concentration of 1 μg/μl. The presence
of VP40 and GP proteins in the purified preparations was
analyzed by SDS-PAGE followed by Western blot using
antibodies against Ebola viral proteins or Coomassie blue
staining.
Examination of EBOV VLP by electron microscopy
For EM study of VLP budding from insect cells, Sf9 cells
were infected with rBV-VP40 at an MOI of 2. At 24 h post-
infection, the cells were fixed with 2% glutaraldehyde and then
with 2% osmium tetroxide. Thin-section samples were prepared
and examined with a transmission electron microscope. For EM
study of purified VLPs, VLP preparations from Sf9 cells
coinfected with rBV-VP40 plus rBV-GP or with rBV-GP or
rBV-VP40 alone were stained with 1% uranyl acetate and then
examined under a Hitachi-H7500 transmission electron
microscope.
Production of Ebola VLPs in 293T cell
The genes for Ebola VP40 and GP proteins were cloned into
the plasmid vector pcDNA3 under the CMV promoter. 293T
cells were seeded in T175 flasks over night and then transfected
with pcDNA3-VP40 and pcDNA3-GP using Polyfect (Qiagen)
following manufacture's protocols. At 48 h post-transfection,
the cell supernatant was collected, and VLPs were purified by
centrifugation through a 20% sucrose cushion at 30K RPM in a
Beckman SW41 rotor. VLPs were resuspended in PBS at about
0.5 μg/μl for characterization by Western blot as well as
stimulation of DCs.
Stimulation of dendritic cells and detection of cytokine
secretion
Human myeloid dendritic cells were prepared from human
PBMC as described in our previous studies (Agrawal et al.,2003; Mahanty et al., 2003). Briefly, PBMC were obtained by
aphresis from healthy human donors. Monocyte-derived DC
was generated by culturing purified monocytes (Ficoll, and
CD14 MACs beads, Miltenyi Biotech) in RPMI 1640 with 10%
FBS for 6 days in the presence of GM-CSF (100 ng/ml) and IL-
4 (5 ng/ml). This resulted in enrichment for CD11c+ CD1a
+HLA-DR+ MDDC (>90%). On day 6 of culture, 0.5 × 106/ml
of immature human myeloid DCs from two different donors
were each stimulated in vitro with 10 μg of each respective VLP
preparations as indicated in figure legends (Ebola GP, GP/
VP40, VP40, or Ebola VLPs produced in mammalian 293T
cells), as well as with LPS (10 ng/ml, positive control), or with
untreated media (negative control) in 12-well plates in
duplicates. Supernatants were harvested after 24 h of incubation
at 37 °C in 5% CO2. Cytokine levels in cell supernatants were
measured by ELISA in duplicates using commercially available
kits (BD Pharmigen, R&D) for IL-6, IL-8, IL-10, IL-12, as well
as TNF-alpha according to the manufacturer's instruction. The
stimulation experiments were repeated once to ensure consis-
tency of obtained results. The results shown represent typical
results obtained from two different stimulation experiments and
error bars represent standard deviations. Significance of
statistical differences in the levels of secreted cytokines
stimulated by VP40-GP VLPs or GP vesicle preparations was
determined by a t test.
Immunization of mice and sample collection
Female BALB/c mice (8 weeks old) were obtained from
Charles River Laboratory and housed at the Emory University
Animal Facility in micro-isolator cages. Groups of mice (six per
group) were immunized with a total of 50 μg of indicated
purified VLP preparations per mouse by intra-muscular
injection with 25 μl VLP preparation per side in both side
quadriceps, followed by boosting with the same dose of VLPs at
weeks 4 and 8. Blood samples were collected from the retro-
orbital sinus under anesthesia at 1 week prior to the first
immunization and 2 weeks after each immunization, and serum
samples were collected and stored at −80 °C until further
analysis.
ELISA
The coding sequence for the Ebola virus GP1 subunit was
linked in frame to the 5′ of a DNA segment encoding for 6
Histidines followed by a stop codon. The gene for the GPI-
histag fusion protein was cloned into the transfer vector pRB21
for generation of recombinant vaccinia viruses expressing the
Ebola GP1-histag fusion protein. His-tagged GP1 proteins were
expressed in HeLa cells by infection with the recombinant
vaccinia virus and purified using Ni-NTA agarose beads
(Qiagen). Ebola virus-specific antibodies were measured in
individual mouse serum samples by an enzyme-linked immu-
noabsorbent assay (ELISA) using purified GP1-histag proteins
as coating antigens. Briefly, the assays were performed in 96-
well polystyrene microtiter plates (Nunc) coated overnight at
4 °C with purified GP1-histag proteins at a concentration of
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for 2 h on coated and blocked ELISA plates, and the bound
immunoglobulins were detected with horseradish peroxidase-
labeled goat antibodies against mouse IgG, IgG1, or IgG2a
(Southern Biotechnology Associates). The wells were devel-
oped with TMB (Sigma). The color reaction was stopped with
hydrochloric acid (0.2N) and the absorbance at 450 nm was read
in an EL312 Bio-Kinetics microplate reader (Bio-Tek Instru-
ments Inc., Winooski, VT). A standard curve was constructed
by coating each ELISA plate with serial 2-fold dilutions of
purified mouse IgG, IgG1, or IgG2a with known concentra-
tions, respectively, and the concentrations of Ebola GP-specific
antibodies in serum samples were calculated using obtained
standard curves and expressed as the amount of antigen-specific
antibody in 1 ml of serum samples (ng/ml).
Neutralization assay
Neutralizing antibodies against Ebola GP were analyzed
using a single-round infectivity assay adapted from an assay
system used in our previous studies of HIV (Bu et al., 2004;
Ye et al., 2004). This assay is based on an indicator cell line,
JC53-BL, which is a derivative of HeLa cells and contains
reporter cassettes of β-galactosidase under an HIV-1 LTR that
is activated by expression of the HIV Tat protein (Derdeyn et
al., 2000; Wei et al., 2003). The Ebola GP pseudotyped HIV
was prepared by cotransfection of 293T cells with DNA
vectors for the HIV backbone and the Ebola GP and the titer
of the pseudotyped virus was determined in the JC53BL cells.
Typically a titer of approximately 105 pfu (blue plaque
forming units) per ml was obtained. For analysis of
neutralizing antibodies, dilutions of heat-inactivated serum
samples were incubated with 100 pfu of pseudotyped virus in
a 96-well plate for 1 h at 37 °C and then added to JC53BL
cells in the presence of DEAE-dextran and incubated for 2
days at 37 °C. Cells were then stained for β-galactosidase
expression. Neutralization was calculated as the percentage of
reduction of the number of blue cells in sample wells, which
were infected with pseudotyped virus incubated with serum
samples, in comparison to the control wells, which were
infected with the same dose of pseudotyped virus incubated
with the same dilution of group-matched preimmune serum
samples [(the number of blue cells in control wells-the number
of blue cells in sample wells)/(the number of blue cells in
control wells) × 100%].
Acknowledgments
This work was supported by Public Service Grants
AI053514, AI057266, AI048638, AI056499, DK057665,
AI056957, and AI057157 from the National Institute of Health.
References
Agrawal, S., Agrawal, A., Doughty, B., Gerwitz, A., Blenis, J., Van Dyke, T.,
Pulendran, B., 2003. Cutting edge: different Toll-like receptor agonists
instruct dendritic cells to induce distinct Th responses via differentialmodulation of extracellular signal-regulated kinase-mitogen-activated
protein kinase and c-Fos. J. Immunol. 171, 4984–4989.
Bachmann, M.F., Zinkernagel, R.M., 1996. The influence of virus structure on
antibody responses and virus serotype formation. Immunol. Today 17,
553–558.
Bachmann, M.F., Rohrer, U.H., Kundig, T.M., Burki, K., Hengartner, H.,
Zinkernagel, R.M., 1993. The influence of antigen organization on B cell
responsiveness. Science 262, 1448–1451.
Bavari, S., Bosio, C.M., Wiegand, E., Ruthel, G., Will, A.B., Geisbert, T.W.,
Hevey, M., Schmaljohn, C., Schmaljohn, A., Aman, M.J., 2002. Lipid raft
microdomains: a gateway for compartmentalized trafficking of Ebola and
Marburg viruses. J. Exp. Med. 195, 593–602.
Bertolotti-Ciarlet, A., Ciarlet, M., Crawford, S.E., Conner, M.E., Estes, M.K.,
2003. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like
particles produced by a dual baculovirus expression vector and
administered intramuscularly, intranasally, or orally to mice. Vaccine 21,
3885–3900.
Borio, L., Inglesby, T., Peters, C.J., Schmaljohn, A.L., Hughes, J.M.,
Jahrling, P.B., Ksiazek, T., Johnson, K.M., Meyerhoff, A., O'Toole, T.,
Ascher, M.S., Bartlett, J., Breman, J.G., Eitzen Jr., E.M., Hamburg, M.,
Hauer, J., Henderson, D.A., Johnson, R.T., Kwik, G., Layton, M.,
Lillibridge, S., Nabel, G.J., Osterholm, M.T., Perl, T.M., Russell, P.,
Tonat, K., Working Group on Civilian Biodefense, 2002. Hemorrhagic
fever viruses as biological weapons: medical and public health
management. JAMA 287, 2391–2405.
Bosio, C.M., Moore, B.D., Warfield, K.L., Ruthel, G., Mohamadzadeh, M.,
Aman, M.J., Bavari, S., 2004. Ebola and Marburg virus-like particles
activate human myeloid dendritic cells. Virology 326, 280–287.
Bu, Z., Ye, L., Vzorov, A., Taylor, D., Compans, R.W., Yang, C., 2004.
Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation
of the Tyr-based endocytosis motif in the cytoplasmic domain. Virology 328,
62–73.
Derdeyn, C.A., Decker, J.M., Sfakianos, J.N., Wu, X., O'Brien, W.A., Ratner,
L., Kappes, J.C., Shaw, G.M., Hunter, E., 2000. Sensitivity of human
immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by
coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74,
8358–8367.
Elliott, L.H., Sanchez, A., Holloway, B.P., Kiley, M.P., McCormick, J.B., 1993.
Ebola protein analyses for the determination of genetic organization. Arch.
Virol. 133, 423–436.
Enserink, M., 2003. Virology. New vaccine and treatment excite Ebola
researchers. Science 302, 1141–1142.
Feldmann, H., Jones, S., Klenk, H.D., Schnittler, H.J., 2003. Ebola virus: from
discovery to vaccine. Nat. Rev., Immunol. 3, 677–685.
Freed, E.O., 2002. Viral late domains. J. Virol. 76, 4679–4687.
Geisbert, T.W., Jahrling, P.B., 2003. Towards a vaccine against Ebola virus.
Expert. Rev. Vaccines 2, 777–789.
Geisbert, T.W., Jahrling, P.B., 2004. Exotic emerging viral diseases: progress
and challenges. Nat. Med. 10 (12 Suppl), S110–S121.
Hart, M.K., 2003. Vaccine research efforts for filoviruses. Int. J. Parasitol. 33,
583–595.
Hevey, M., Negley, D., Pushko, P., Smith, J., Schmaljohn, A., 1998. Marburg
virus vaccines based upon alphavirus replicons protect guinea pigs and
nonhuman primates. Virology 251, 28–37.
Jarves, D.L., Finn, E.E., 1995. Biochemical analysis of the N-glycosylation
pathway in baculovirus-infected lepidopteran insect cells. Virology 212,
500–511.
Jasenosky, L.D., Neumann, G., Lukashevich, I., Kawaoka, Y., 2001. Ebola virus
VP40-induced particle formation and association with the lipid bilayer.
J. Virol. 75, 5205–5214.
Li, T.C., Yamakawa, Y., Suzuki, K., Tatsumi, M., Razak, M.A., Uchida, T.,
Takeda, N., Miyamura, T., 1997. Expression and self-assembly of empty
virus-like particles of hepatitis E virus. J. Virol. 71, 7207–7213.
Mahanty, S., Hutchinson, K., Agarwal, S., McRae, M., Rollin, P.E., Pulendran,
B., 2003. Cutting edge: impairment of dendritic cells and adaptive immunity
by Ebola and Lassa viruses. J. Immunol. 170, 2797–2801.
Mellquist-Riemenschneider, J.L., Garrison, A.R., Geisbert, J.B., Saikh, K.U.,
Heidebrink, K.D., Jahrling, P.B., Ulrich, R.G., Schmaljohn, C.S., 2003.
270 L. Ye et al. / Virology 351 (2006) 260–270Comparison of the protective efficacy of DNA and baculovirus-derived
protein vaccines for EBOLA virus in guinea pigs. Virus Res. 92, 187–193.
Montefiori, D.C., Safrit, J.T., Lydy, S.L., Barry, A.P., Bilska, M., Vo, H.T.,
Klein, M., Tartaglia, J., Robinson, H.L., Rovinski, B., 2001. Induction of
neutralizing antibodies and gag-specific cellular immune responses to an R5
primary isolate of human immunodeficiency virus type 1 in rhesus
macaques. J. Virol. 75, 5879–5890.
Nabel, G.J., 2003. Vaccine for AIDS and Ebola virus infection. Virus Res. 92,
213–217.
Noda, T., Sagara, H., Suzuki, E., Takada, A., Kida, H., Kawaoka, Y., 2002.
Ebola virus VP40 drives the formation of virus-like filamentous particles
along with GP. J. Virol. 76, 4855–4865.
Park, J.S., Oh, Y.K., Kang, M.J., Kim, C.K., 2003. Enhanced mucosal and
systemic immune responses following intravaginal immunization with
human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive
mucoadhesive delivery systems. J. Med. Virol. 70, 633–641.
Pestka, S., Krause, C.D., Sarkar, D., Walter, M.R., Shi, Y., Fisher, P.B., 2004.
Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22,
929–979.
Pushko, P., Bray, M., Ludwig, G.V., Parker, M., Schmaljohn, A., Sanchez,
A., Jahrling, P.B., Smith, J.F., 2000. Recombinant RNA replicons
derived from attenuated Venezuelan equine encephalitis virus protect
guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19,
142–153.
Sanchez, A., Kiley, M.P., Holloway, B.P., Auperin, D.D., 1993. Sequence
analysis of the Ebola virus genome: organization, genetic elements, and
comparison with the genome of Marburg virus. Virus Res. 29, 215–240.
Sanchez, A., Yang, Z.Y., Xu, L., Nabel, G.J., Crews, T., Peters, C.J., 1998.
Biochemical analysis of the secreted and virion glycoproteins of Ebola virus.
J. Virol. 72, 6442–6447.
Sullivan, N.J., Sanchez, A., Rollin, P.E., Yang, Z.Y., Nabel, G.J., 2000.
Development of a preventive vaccine for Ebola virus infection in primates.
Nature 408, 605–609.
Sullivan, N.J., Geisbert, T.W., Geisbert, J.B., Xu, L., Yang, Z.Y., Roederer, M.,
Koup, R.A., Jahrling, P.B., Nabel, G.J., 2003. Accelerated vaccination for
Ebola virus haemorrhagic fever in non-human primates. Nature 424,
681–684.
Swenson, D.L., Warfield, K.L., Negley, D.L., Schmaljohn, A., Aman, M.J.,
Bavari, S., 2005. Virus-like particles exhibit potential as a pan-filovirusvaccine for both Ebola and Marburg viral infections. Vaccine 23,
3033–3042.
Volchkov, V.E., Feldmann, H., Volchkova, V.A., Klenk, H.D., 1998. Processing
of the Ebola virus glycoprotein by the proprotein convertase furin. Proc.
Natl. Acad. Sci. U.S.A. 95, 5762–5767.
Wahl-Jensen, V., Kurz, S.K., Hazelton, P.R., Schnittler, H.J., Stroher, U., Burton,
D.R., Feldmann, H., 2005. Role of Ebola virus secreted glycoproteins and
virus-like particles in activation of human macrophages. J. Virol. 79,
2413–2419.
Warfield, K.L., Bosio, C.M., Welcher, B.C., Deal, E.M., Mohamadzadeh, M.,
Schmaljohn, A., Aman, M.J., Bavari, S., 2003. Ebola virus-like particles
protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. U.S.A. 100,
15889–15894.
Warfield, K.L., Swenson, D.L., Negley, D.L., Schmaljohn, A.L., Aman, M.J.,
Bavari, S., 2004. Marburg virus-like particles protect guinea pigs from lethal
Marburg virus infection. Vaccine 22, 3495–3502.
Warfield, K.L., Olinger, G., Deal, E.M., Swenson, D.L., Bailey, M., Negley,
D.L., Hart, M.K., Bavari, S., 2005. Induction of humoral and CD8+ T cell
responses are required for protection against lethal Ebola virus infection.
J. Immunol. 175, 1184–1191.
Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-
Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., Komarova, N.L.,
Nowak, M.A., Hahn, B.H., Kwong, P.D., Shaw, G.M., 2003. Antibody
neutralization and escape by HIV-1. Nature 422, 307–312.
WHO, 2005. Marburg Haemorrhagic fever in Angola—Update 20.
Yamshchikov, G.V., Ritter, G.D., Vey, M., Compans, R.W., 1995. Assembly of
SIV virus-like particles containing envelope proteins using a baculovirus
expression system. Virology 214, 50–58.
Yao, Q., Compans, R.W., Chen, C., 2001. HIV envelope proteins differentially
utilize CXCR4 and CCR5 coreceptors for induction of apoptosis. Virology
285, 128–137.
Yao, Q., Vuong, V., Li, M., Compans, R.W., 2002. Intranasal immunization with
SIV virus-like particles (VLPs) elicits systemic and mucosal immunity.
Vaccine 20, 2537–2545.
Yao, Q., Bu, Z., Vzorov, A., Yang, C., Compans, R.W., 2003. Virus-like particle
and DNA-based candidate AIDS vaccines. Vaccine 21, 638–643.
Ye, L., Bu, Z., Vzorov, A., Taylor, D., Compans, R.W., Yang, C., 2004. Surface
stability and immunogenicity of the HIV envelope glycoprotein: the role of
the cytoplasmic domain. J. Virol. 78, 13409–13419.
